Purple Pen Podcast

Purple Pen Podcast

Education and news for pharmacists, with a focus on Australian clinical pharmacy practice. Hosted by Kristin Xenos and Natalie Tasker, we provide CPD and news for pharmacists, especially those interested in Australian clinical practice. Created by Jane Booth and Dan Guidone.

  1. hace 3 días

    PPP 193 - Childhood Cancer in First Nations People with Dr Jessica Buck

    To align with NAIDOC week this year we have a special bonus episode. In this episode, we speak with Dr Jessica Buck about childhood cancer in First Nations people, genomics, and the importance of cultural safety in healthcare and research. A proud Kamilaroi woman, she is the Team Leader of the First Nations Childhood Cancer Program at The Kids Research Institute Australia — a first-of-its-kind initiative dedicated to developing culturally safe, community-led research strategies to improve outcomes for First Nations children with cancer. Together, we explore how a First Nations perspective can strengthen biomedical science and improve care for Aboriginal and Torres Strait Islander children and families affected by cancer. We cover: What culturally safe healthcare and research look like in practice Applying a First Nations lens to genomics and biomedical science How historical harms in healthcare and research continue to influence trust today Childhood cancer outcomes for First Nations children The impact of geography, access to care, racism and broader inequities Why representation in genomic databases and clinical trials matters The clinical implications of underrepresentation for diagnosis and treatment The potential role of pharmacogenomics in cancer care Treatment-related adverse effects Opportunities to improve equity in childhood cancer care   Further reading and resources: Clark (Adnyamathanha), J.R., Buck (Kamilaroi), J., Richards-Satour (Adnyamathanha and Barngarla), A., Lyons (Jaadwa), L. and Brown (Yuin), A. (2024), Towards precision cancer medicine for Aboriginal and Torres Strait Islander cancer health equity. Med J Aust, 221: 68-73. https://doi.org/10.5694/mja2.52346 https://onlinelibrary.wiley.com/doi/10.5694/mja2.52346   Alexandra Truong, Kayla Williams‐Tucker (Ngarluma, Wongutha, Wudjari Noongar), Ahmi Narkle (Whadjuk Goreng Noongar), Eden Slicer (Gundungurra), Jessica‐Elise Chapman (Kamilaroi, Bundjalung), Jessica Lawler, Rishi S Kotecha, Hetal Dholaria, Justine R Clark (Adnyamathanha), Alex Brown (Yuin), Raelene Endersby, Nicholas G Gottardo and Jessica Buck (Kamilaroi) - Current gaps in knowledge and future research directions for Aboriginal and Torres Strait Islander children with cancer - https://www.mja.com.au/journal/2025/222/10/current-gaps-knowledge-and-future-research-directions-aboriginal-and-torres  The Kids Research Institute Australia https://www.thekids.org.au/our-research/chronic-diseases/first-nations-childhood-cancer/   Zero Childhood Cancer https://www.zerochildhoodcancer.org.au/  Henrietta Lacks: science must right a historical wrong - https://www.nature.com/articles/d41586-020-02494-z    A note on the artwork for this episode: "Cancer 2025" Shaznaye Bin-Kali, is a Kija and Yawuru Jij from Broome, W.A. She is 15 years old. She was diagnosed with brain cancer at six months old and experienced her first seizure at the age of one, which led to her first operation. This painting represents the spread of her brain cancer. The lines surrounding it symbolise her very first seizure, an important moment in my journey. Through her art, she shares her story, resilience, and connection to her culture.   Note: NAIDOC stands for the National Aborigines and Islanders Day Observance Committee. It aims to celebrate and recognise the history, culture and achievements of Aboriginal and Torres Strait Islander peoples.

    32 min
  2. 16 may

    PPP 190 - Osteoporosis with Dr Mariya Farah Kitson

    In this episode, we're joined by Dr Mariya Farah Kitson, Consultant Rheumatologist at the Osteoporosis Refracture Prevention Clinic at Royal North Shore Hospital, for a deep dive into the diagnosis and management of osteoporosis. We explore why osteoporosis remains significantly underdiagnosed, current recommendations for bone mineral density (BMD) screening, and the ongoing osteoporosis care gap that leaves many patients untreated after fragility fractures. Dr Kitson also explains the role of secondary fracture prevention services and why menopause represents a particularly high-risk period for accelerated bone loss and fracture risk in women. The conversation also unpacks the evolving treatment landscape for osteoporosis, including discussions around denosumab, its PBS and other indications, and important considerations regarding duration of therapy and rebound vertebral fracture risk following discontinuation. Dr Kitson compares the mechanisms of action of denosumab and bisphosphonates, outlines current recommendations for safely stopping denosumab, and discusses where newer therapies such as romosozumab fit into contemporary osteoporosis care. We also touch on the emerging role of biomarkers in fracture risk assessment and treatment monitoring, offering listeners an up-to-date and clinically relevant overview of osteoporosis management.   Further Links  ASBMR - The American Society for Bone and Mineral Research - https://www.asbmr.org/Default.aspx  International Osteoporosis Foundation https://www.osteoporosis.foundation/

    35 min
  3. 14 mar

    PPP 188 - Menopause Part 2 with Jarrah Anderson and Bo Youn Kim

    Kristin speaks with two pharmacists working in menopause care: Bo Kim, clinical pharmacist and founder of EmpowHer Menopause in Perth Jarrah Anderson, Clinical Lead at MedCast and member of the Quality Use of Medicines Alliance In this episode Types of menopausal hormone treatment (MHT) When different MHT options are used in perimenopause and menopause. Safety conversations Current thinking on precautions and contraindications, and how to explain risks and benefits clearly. Access and cost in Australia PBS considerations, affordability and opportunities for pharmacist support. Bio‑identical and body‑identical hormones Why it matters for patient communication. Testosterone in menopause care What the evidence says about when it can be used and practical issues with prescribing and access. Non‑hormonal therapies Options for symptom management, including the emerging medicine fezolinetant. Links: Medcast Qhub - quality use of medicines resources - https://medcast.com.au/qhub    Australian Menopause Society Complementary medicines and therapies: options for menopausal symptoms - https://hub.menopause.org.au/Play?pId=3234710f-e5db-4aa1-bff8-ae98449fffad    Guide to MHT/HRT Doses - https://hub.menopause.org.au/Play?pId=6ecead60-db26-4dfc-a662-794d7b39ef59   Jean Hailes  Perimenopause and menopause symptom checklist https://jeanhailes.org.au/wp-content/uploads/2026/01/Perimenopause-and-menopause-symptom-checklist_TGD.pdf

    34 min

Acerca de

Education and news for pharmacists, with a focus on Australian clinical pharmacy practice. Hosted by Kristin Xenos and Natalie Tasker, we provide CPD and news for pharmacists, especially those interested in Australian clinical practice. Created by Jane Booth and Dan Guidone.

También te podría interesar